Pharmaceuticals News and Research

RSS

Sanford-Burnham, Daiichi enter into comprehensive alliance to develop first-in-class therapeutics

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases.

22 May 2014

Researchers identify existing drugs that could be "repurposed" to fight MERS-CoV

A team led by a University of Maryland School of Medicine (UM SOM) researcher, working as a grantee from the National Institutes of Health (NIH), has identified a number of existing drugs that could be "repurposed" to fight outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).

22 May 2014

Lucideon invests in an Agilent 7900 Quadrapole ICP-MS to extend its analysis techniques offerings

Lucideon, the international provider of materials development, testing and assurance, and formerly known as Ceram, is pleased to announce it has invested in the latest Agilent 7900 Quadrapole Inductively Coupled Plasma – Mass Spectrometry (ICP-MS).

From Lucideon 21 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Isis Pharmaceuticals starts Phase 1 clinical study of ISIS-PKKRx to treat patients with HAE

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx. ISIS-PKKRx is an antisense drug in development to treat patients with hereditary angioedemia (HAE).

21 May 2014

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Edison Pharmaceuticals has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Cardiome Pharma Corp. today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets.

20 May 2014

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014.

20 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

PAREXEL International launches Perceptive MyTrials Data-Driven Monitoring solution

PAREXEL International, a leading global biopharmaceutical services organization, today announced the launch of its Perceptive MyTrials® Data-Driven Monitoring solution.

From Parexel 20 May 2014

BroadcastMed introduces content marketing platform for pharmaceutical, biotechnology organizations

BroadcastMed, Inc. a digital medical broadcaster and leading provider of cloud based physician education portals introduces its content marketing platform tailored to pharmaceutical and biotechnology organizations.

20 May 2014

Home testing and CPAP therapy initiation for OSA may reduce costs without sacrificing clinical outcomes

Home testing of obstructive sleep apnea (OSA) followed by initiation of home treatment with an auto-titrating continuous positive airway pressure (CPAP) device reduced costs compared with in-laboratory testing and titration without negatively impacting clinical outcomes, researchers have shown in a new study presented at the American Thoracic Society International Conference.

20 May 2014

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Biovision, the annual forum on future-oriented research in life sciences, today announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer sessions. Awards will be presented during the closing ceremony.

20 May 2014

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Leaders from academic institutions, non-profit organizations, and pharmaceutical companies will meet in Cambridge, Mass., on Monday, May 19, to discuss biomarkers in amyotrophic lateral sclerosis (ALS).

19 May 2014

Auxilium Pharmaceuticals presents new XIAFLEX clinical trial data at AUA Meeting

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD).

19 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work.

19 May 2014

IFRC, IFPMA launch '4 Healthy Habits' initiative to combat noncommunicable diseases

The International Federation of Red Cross and Red Crescent Societies (IFRC) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) launch today, during a side event at the 67th World Health Assembly, a global initiative, called '4 Healthy Habits'.

19 May 2014

Pharmaceuticals News and Research

Sanford-Burnham, Daiichi enter into comprehensive alliance to develop first-in-class therapeutics

Researchers identify existing drugs that could be "repurposed" to fight MERS-CoV

Lucideon invests in an Agilent 7900 Quadrapole ICP-MS to extend its analysis techniques offerings

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Isis Pharmaceuticals starts Phase 1 clinical study of ISIS-PKKRx to treat patients with HAE

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

BioLineRx announces financial results for Q1 2014, provides operational update

Existing pharmaceutical drugs may offer effective therapies against MERS

PAREXEL International launches Perceptive MyTrials Data-Driven Monitoring solution

BroadcastMed introduces content marketing platform for pharmaceutical, biotechnology organizations

Home testing and CPAP therapy initiation for OSA may reduce costs without sacrificing clinical outcomes

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Pharmaceutical and academic leaders come together to discuss biomarkers in ALS

Auxilium Pharmaceuticals presents new XIAFLEX clinical trial data at AUA Meeting

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Shire intends to submit NDA for lifitegrast to treat dry eye disease

IFRC, IFPMA launch '4 Healthy Habits' initiative to combat noncommunicable diseases

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence